Muder Daniel, Hailer Nils P, Vedung Torbjörn
Department of Surgical Sciences/Orthopedics & Hand Surgery, Uppsala University, Entrance 70, 751 85, Uppsala, Sweden.
Department of Orthopedics, Falu Lasarett, Lasarettsvägen 10, 791 82, Falun, Sweden.
BMC Musculoskelet Disord. 2020 Oct 7;21(1):657. doi: 10.1186/s12891-020-03687-3.
The aim of our study was to compare the long-term outcome after perichondrium transplantation and two-component surface replacement (SR) implants to the metacarpophalangeal (MCP) and the proximal interphalangeal (PIP) joints.
We evaluated 163 joints in 124 patients, divided into 138 SR implants in 102 patients and 25 perichondrium transplantations in 22 patients. Our primary outcome was any revision surgery of the index joint.
The median follow-up time was 6 years (0-21) for the SR implants and 26 years (1-37) for the perichondrium transplants. Median age at index surgery was 64 years (24-82) for SR implants and 45 years (18-61) for perichondium transplants. MCP joint survival was slightly better in the perichondrium group (86.7%; 95% confidence interval [CI]: 69.4-100.0) than in the SR implant group (75%; CI 53.8-96.1), but not statistically significantly so (p = 0.4). PIP joint survival was also slightly better in the perichondrium group (80%; CI 55-100) than in the SR implant group (74.7%; CI 66.6-82.7), but below the threshold of statistical significance (p = 0.8).
In conclusion, resurfacing of finger joints using transplanted perichondrium is a technique worth considering since the method has low revision rates in the medium term and compares favorable to SR implants.
III (Therapeutic).
我们研究的目的是比较软骨膜移植和双组分表面置换(SR)植入物应用于掌指(MCP)关节和近端指间(PIP)关节后的长期疗效。
我们评估了124例患者的163个关节,其中102例患者使用了138个SR植入物,22例患者进行了25次软骨膜移植。我们的主要结局指标是目标关节的任何翻修手术。
SR植入物的中位随访时间为6年(0 - 21年),软骨膜移植的中位随访时间为26年(1 - 37年)。目标手术时,SR植入物组的中位年龄为64岁(24 - 82岁),软骨膜移植组为45岁(18 - 61岁)。软骨膜组MCP关节的生存率略高于SR植入物组(86.7%;95%置信区间[CI]:69.4 - 100.0),但差异无统计学意义(p = 0.4)。软骨膜组PIP关节的生存率也略高于SR植入物组(80%;CI 55 - 100),但低于统计学意义阈值(p = 0.8)。
总之,使用移植软骨膜进行手指关节表面置换是一种值得考虑的技术,因为该方法中期翻修率低,与SR植入物相比具有优势。
III(治疗性)。